Meeting
2018 ASCO Annual Meeting
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Authors
Lajos Pusztai
Yale Cancer Center, New Haven, CT
Lajos Pusztai , Erin Wysong Hofstatter , Gina G. Chung , Nina Ruth Horowitz , Donald R. Lannin , Brigid K. Killelea , Anees B. Chagpar , Michael DiGiovanna , Courtney Frederick , Trisha Burello , Malini Harigopal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02489448
Citation
J Clin Oncol 36, 2018 (suppl; abstr 586)
DOI
10.1200/JCO.2018.36.15_suppl.586
Abstract #
586
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.
First Author: Lajos Pusztai
Poster
2013 ASCO Annual Meeting
Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC).
First Author: Jessica Nicole Snider
Poster
2012 ASCO Annual Meeting
Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
First Author: Jessica N. Snider
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force